Navigation Links
NxStage Medical Reports Third Quarter 2007 Results
Date:11/2/2007

(16,124) (9,576) (40,999) (29,218)

Net loss per share, basic and diluted $(0.54) $(0.34) $(1.38) $(1.23)

Weighted-average shares outstanding,

basic and diluted 30,024 27,761 29,667 23,819

NxStage Medical, Inc.

Consolidated Balance Sheets

(in thousands, except per share data)

(Unaudited)

September 30, December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $32,383 $49,959

Short-term investments 500 11,843

Accounts receivable, net 6,061 4,302

Inventory 15,319 10,419

Prepaid expenses and other current assets 703 1,014

Total current assets 54,966 77,537

Property and equipment, net 4,799 3,026

Field equipment, net 26,866 20,616

Deferred cost of revenues 11,691 140

Other assets 2,661 406

Total assets $100,983 $101,725

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $9,947 $5,917

Accrued expenses 5,705 4,104

Current portion of long-term debt 2,800 2,800

Total current liabilities 18,452 12,821

Deferred rent obligation
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 1H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 2H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 3Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 1Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 2PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 1PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 2